<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7463036\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Abstract Background Oseltamivir is a first-line antiviral drug, especially in" exact="primary" post="hospitals. During the ongoing outbreak of coronavirus disease 2019"/>
  <result pre="especially in primary hospitals. During the ongoing outbreak of coronavirus" exact="disease" post="2019 (COVID-19), most patients with COVID-19 who are symptomatic"/>
  <result pre="coronavirus disease 2019 (COVID-19), most patients with COVID-19 who are" exact="symptomatic" post="have used oseltamivir. Considering its popular and important role"/>
  <result pre="papain-like protease (PLpro), and RNA-directed RNA polymerase (RdRp) of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). TM-align program was performed"/>
  <result pre="protease (PLpro), and RNA-directed RNA polymerase (RdRp) of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). TM-align program was performed to"/>
  <result pre="(PLpro), and RNA-directed RNA polymerase (RdRp) of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). TM-align program was performed to compare"/>
  <result pre="TM-align program was performed to compare the structure of the" exact="viral" post="proteins with the structure of the neuraminidase of influenza"/>
  <result pre="effective binding of oseltamivir with the active centers of the" exact="viral" post="proteins. In vitro study was used to evaluate the"/>
  <result pre="the patientsâ€™ symptoms and signs and did not slow the" exact="disease" post="progression. Conclusions We consider that oseltamivir isnâ€™t suitable for"/>
  <result pre="A and influenza B and is becoming more widespread. The" exact="atypical pneumonia" post="caused by severe acute respiratory syndrome coronavirus (SARS-CoV) that"/>
  <result pre="and influenza B and is becoming more widespread. The atypical" exact="pneumonia" post="caused by severe acute respiratory syndrome coronavirus (SARS-CoV) that"/>
  <result pre="is becoming more widespread. The atypical pneumonia caused by severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) that broke out in Guangzhou,"/>
  <result pre="becoming more widespread. The atypical pneumonia caused by severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) that broke out in Guangzhou, China,"/>
  <result pre="more widespread. The atypical pneumonia caused by severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) that broke out in Guangzhou, China, in"/>
  <result pre="found that the active site of the Spike (S) 1" exact="Protein" post="of SARS is similar to that of neuraminidase, suggesting"/>
  <result pre="is effective in treating SARS-CoV. With the epidemic of coronavirus" exact="disease" post="2019 (COVID-19) caused by SARS-CoV-2, oseltamivir has once again"/>
  <result pre="this case and found most patients with COVID-19 who were" exact="symptomatic" post="have used oseltamivir. We believed that it is of"/>
  <result pre="in common households but also a common antiviral drug in" exact="primary" post="hospitals. Therefore, if oseltamivir is effective for COVID-19, the"/>
  <result pre="key enzymes of SARS-CoV-2 are important targets for inhibiting SARS-CoV-2" exact="infection" post="[6], [7], [8], [9], [10]. Since the SARS outbreak"/>
  <result pre="conditions of patients with COVID-19. 2 Methods 2.1 Obtaining the" exact="viral" post="protein structure The structures of the S protein (PDB"/>
  <result pre="3CL pro (PDB ID: 6LU7) were downloaded from the RCSB" exact="Protein" post="Data Bank (http://www.rcsb.org). The structures of NC, PLpro, and"/>
  <result pre="[19], [20], [21]. 2.3 Alignment of the structure of a" exact="viral" post="protein and the structure of influenza a neuraminidase TM-align"/>
  <result pre="as a positive control. 2.4 Molecular docking of oseltamivir with" exact="viral" post="protein We used ChemBioDraw Ultra 17.0 software to draw"/>
  <result pre="before infecting with the SARS-CoV-2 (nCoV-2019BetaCoV/Wuhan/WIV04/2019) at a multiplicity of" exact="infection" post="(MOI) of 0.05 for 2Â h. After that, cell"/>
  <result pre="h. After that, cell culture supernatants were replaced with fresh" exact="complete" post="medium containing different concentrations of oseltamivir. Virus-containing supernatants were"/>
  <result pre="at 24h after transfection for extracting RNA by the MiniBEST" exact="Viral" post="RNA/DNA Extraction Kit (Takara, CAT No. 9766) according to"/>
  <result pre="The qRT-PCR assay was conducted to evaluate the quantification of" exact="viral" post="copy numbers in the cell supernatant with TB Green"/>
  <result pre="Study design We retrospectively analyzed 627 patients diagnosed with SARS-CoV-2" exact="infection" post="at the Second Hospital of Wuhan, Wuhan Union Hospital,"/>
  <result pre="The enrollment criteria were: 1. patients were diagnosed with SARS-CoV-2" exact="infection" post="and negative for influenza A and B nucleic acid"/>
  <result pre="there were no other underlying diseases, such as hypertension, diabetes," exact="cardiovascular" post="and cerebrovascular diseases, malignant diseases, no respiratory tract diseases,"/>
  <result pre="underlying diseases, such as hypertension, diabetes, cardiovascular and cerebrovascular diseases," exact="malignant" post="diseases, no respiratory tract diseases, such as COPD, asthma,"/>
  <result pre="as hypertension, diabetes, cardiovascular and cerebrovascular diseases, malignant diseases, no" exact="respiratory" post="tract diseases, such as COPD, asthma, and pulmonary heart"/>
  <result pre="diseases, no respiratory tract diseases, such as COPD, asthma, and" exact="pulmonary" post="heart disease, and no hypoproteinemia and hypokalemia. We defined"/>
  <result pre="no respiratory tract diseases, such as COPD, asthma, and pulmonary" exact="heart" post="disease, and no hypoproteinemia and hypokalemia. We defined the"/>
  <result pre="treatment period. We defined the patients with relieved symptoms and" exact="stable" post="or absorbed lesions in CT during the treatment period"/>
  <result pre="on Guidelines of the Diagnosis and Treatment of New Coronavirus" exact="Pneumonia" post="(version 7) of National Health Commission of China. Whether"/>
  <result pre="the history of oseltamivir use influenced the progression of the" exact="disease" post="was statistically evaluated. 2.6.2 Data collection Patientsâ€™ information such"/>
  <result pre="as sex and age and their clinical data such as" exact="chest" post="CT, the history of oseltamivir use, the usage and"/>
  <result pre="were considered significant. 3 Result 3.1 The obtainment of the" exact="viral" post="protein structure The structures of the S protein (PDB"/>
  <result pre="(PDB ID: 6LU7) of SARS-CoV-2 were obtained from the RCSB" exact="Protein" post="Data Bank (http://www.rcsb.org). Then the structures of NC, PLpro,"/>
  <result pre="to analyze the compatibility of the 3D structure and the" exact="primary" post="sequence in the model. A 3D-1D scoreÂ â‰¥Â 0.2"/>
  <result pre="model of NRBD, PLpro and Pol/RdRp evaluated through SAVES program." exact="Protein" post="Residues have average 3D-1D score&amp;gt;=0.2 Overall Quality Factor Residues"/>
  <result pre="polymerase; PLpro: papain-like protease. 3.3 Alignment of the structure of" exact="viral" post="proteins and influenza A neuraminidase To explore whether oseltamivir"/>
  <result pre="analyzed whether there was structural similarity between the structure of" exact="viral" post="protein and influenza A neuraminidase (PDB ID: 3Ti6), especially"/>
  <result pre="that Thr680, Asn691, and Asp623 can bind nucleotides and promote" exact="viral" post="gene transcription, and Val557 also plays an important role"/>
  <result pre="from the neuraminidase. Fig. 2 Alignment of the structure of" exact="viral" post="proteins and influenza A neuraminidase analyzed by TM-align program."/>
  <result pre="referred to the web version of this article.) Table 2" exact="Structural" post="alignment analyzed by TM-align program. Protein TM-score Final Influenza"/>
  <result pre="this article.) Table 2 Structural alignment analyzed by TM-align program." exact="Protein" post="TM-score Final Influenza B neuraminidase 0.94460 In about the"/>
  <result pre="acid could stably bind to the active center of the" exact="viral" post="protein structure. The docking conformations were described in Fig."/>
  <result pre="âˆ’5.8Â kcal/mol, and âˆ’5.4Â kcal/mol, respectively (Table 3 ). The" exact="lower" post="the binding energy, the more suitable the binding of"/>
  <result pre="showed that its docking energy was âˆ’8.5Â kcal/mol, which was" exact="lower" post="than that of oseltamivir carboxylic acid. The docking conformation"/>
  <result pre="The calculated binding energy of binding for oseltamivir carboxylic acid." exact="Protein" post="Binding energy (Kcal/mol) NRBD âˆ’4.7 3CLpro âˆ’7.0 PLpro âˆ’5.8"/>
  <result pre="cultured with the treatment of tested drugs for 24Â h." exact="Viral" post="copy numbers in the cell supernatant were quantified by"/>
  <result pre="the efficacy of oseltamivir on SARS-CoV-2, we retrospectively analyzed a" exact="total" post="of 627 patients from the Second Hospital of Wuhan,"/>
  <result pre="oseltamivir in the two groups. In the remission group, a" exact="total" post="of seven patients used oseltamivir with a proportion of"/>
  <result pre="with a proportion of 22.58%. In the non-remission group, a" exact="total" post="of 35 patients used oseltamivir, with a proportion of"/>
  <result pre="COVID-19 and could not effectively slow the progression of the" exact="disease" post="with early use. Table 4 Comparison of the difference"/>
  <result pre="the patientsâ€™ symptoms and signs and did not slow the" exact="disease" post="progression. As a neuraminidase inhibitor, oseltamivir has effectively combated"/>
  <result pre="it is a first-line commonly used antiviral drug, especially in" exact="primary" post="hospitals. At the same time, oseltamivir, as an over-the-counter"/>
  <result pre="fighting against COVID-19, we have found that many patients experiencing" exact="discomfort" post="or considered to be infected with a virus take"/>
  <result pre="We cannot predict whether there will be a pandemic of" exact="respiratory" post="coronavirus in the future, so we hope to initiate"/>
  <result pre="use of DNA vaccineImmunol. Lett.923200423724315081618 13YangH.YangM.DingY.The crystal structures of severe" exact="acute" post="respiratory syndrome virus main protease and its complex with"/>
  <result pre="of DNA vaccineImmunol. Lett.923200423724315081618 13YangH.YangM.DingY.The crystal structures of severe acute" exact="respiratory" post="syndrome virus main protease and its complex with an"/>
  <result pre="DNA vaccineImmunol. Lett.923200423724315081618 13YangH.YangM.DingY.The crystal structures of severe acute respiratory" exact="syndrome" post="virus main protease and its complex with an inhibitorProc."/>
  <result pre="Res.1152015213825554382 15MengB.LuiY.-w.MengS.CaoC.HuY.Identification of effective siRNA blocking the expression of SARS" exact="viral" post="envelope E and RDRP genesMol. Biotechnol.332200614114816757801 16Y.-S. Wu, W.-H."/>
  <result pre="the design of our paper. She is from Department of" exact="Respiratory" post="Medicine, Second Hospital of Wuhan. We thank Leike Zhang"/>
  <result pre="the front line. This work was supported by Novel coronavirus" exact="pneumonia" post="emergency project, China (no. 2020YFC084430), 10.13039/501100013076National Major Science and"/>
  <result pre="of China (CN):2020YFC0844300, and the 10.13039/501100012226Fundamental Research Funds for the" exact="Central" post="Universities , HUST: 2020kfyXGYJ011, 10.13039/501100011198State Key Laboratory of Drug"/>
 </snippets>
</snippetsTree>
